Chotigeat Uraiwan, Ratchatanorravut Sombat, Kanjanapattanakul Wiboon
Division of Neonatology, Queen Sirikit National Institute of Child Health, College of Medicine, Rangsit University, Bangkok, Thailand.
J Med Assoc Thai. 2011 Aug;94 Suppl 3:S35-40.
The utilization of surfactant replacement therapy had been limited in treatment of respiratory distress syndrome (RDS) due to the high cost especially in developing countries. Nowadays, the National Health Insurance Policy has covered the cost of surfactant for the patients. Therefore, bronchopulmonary dysplasia (BPD) may be found increasing due to increased survival in patients with severe RDS.
To compare immediate treatment outcome of severity of BPD and outcome after hospital discharge in neonates with RDS who were treated with or without surfactant.
Retrospective cohort study.
The data of 54 infants who developed BPD after RDS at Queen Sirikit National Institute of Child Health between January 1st, 2003 and December 31th, 2005 were kept in database format. The database was analyzed for difference between groups and the outcome of immediate treatment, severity of BPD and outcome after hospital discharge were compared. The study group was BPD cases from RDS treated with surfactant compared to control (BPD cases from RDS treated without surfactant) groups.
Forty-three (80%) from fifty-four cases had completed data and were included into the present study. There was no statistically significant difference in maternal conditions and neonatal conditions between groups. Antenatal steroid was prescribed more often in RDS without surfactant group than surfactant group. The mean birth weight and gestational age in surfactant and without surfactant groups were 1,179.1 +/- 274.3 gm vs. 1,114.4 +/- 338.3 gm and 29 +/- 1.6 weeks vs. 29.2 +/- 2.7 weeks respectively, but no significant differences were observed between groups. To compare the severity of RDS, only 17.6% of moderate to severe RDS in the control group was found, whereas 100% was found in the study group. Moderate to severe BPD cases were found more often in the control group (70.6%) than in the study group (61.6%), but no statistically significant difference was shown. The immediate complications, e.g. pneumothorax (5.9%) and pneumomediastinum (5.9%) were found in the control group, but pulmonary hemorrhage occurred more often in the study group than the control group (11.5% vs. 5.9%). For long-term follow-up, the development outcome was not different between groups.
The present study revealed no statistically significant difference in severity of BPD in neonates with RDS treated with and without surfactant groups. In addition, surfactant was useful in moderate to severe RDS because no early complication such as air leak syndrome was found in this group.
由于成本高昂,尤其是在发展中国家,表面活性剂替代疗法在呼吸窘迫综合征(RDS)的治疗中应用有限。如今,国家医疗保险政策已涵盖了患者使用表面活性剂的费用。因此,由于重度RDS患者存活率的提高,支气管肺发育不良(BPD)的发生率可能会上升。
比较接受或未接受表面活性剂治疗的RDS新生儿中BPD严重程度的即时治疗结果以及出院后的结局。
回顾性队列研究。
将2003年1月1日至2005年12月31日期间在诗丽吉王后国家儿童健康研究所发生RDS后发展为BPD的54例婴儿的数据以数据库形式保存。分析数据库以比较组间差异,并比较即时治疗结果、BPD严重程度和出院后的结局。研究组为接受表面活性剂治疗的RDS所致BPD病例,对照组为未接受表面活性剂治疗的RDS所致BPD病例。
54例中有43例(80%)完成数据并纳入本研究。两组间产妇情况和新生儿情况无统计学显著差异。未使用表面活性剂的RDS组比使用表面活性剂组更常使用产前类固醇。使用表面活性剂组和未使用表面活性剂组的平均出生体重和胎龄分别为1179.1±274.3克对1114.4±338.3克和29±1.6周对29.2±2.7周,但两组间未观察到显著差异。为比较RDS的严重程度,对照组中仅发现17.6%为中度至重度RDS,而研究组中为100%。对照组中中度至重度BPD病例(70.6%)比研究组(61.6%)更常见,但未显示出统计学显著差异。对照组中发现即时并发症,如气胸(5.9%)和纵隔气肿(5.9%),但研究组中肺出血的发生率高于对照组(11.5%对5.9%)。对于长期随访,两组间发育结局无差异。
本研究显示,接受和未接受表面活性剂治疗的RDS新生儿中BPD严重程度无统计学显著差异。此外,表面活性剂对中度至重度RDS有用,因为该组未发现早期并发症,如空气泄漏综合征。